uniQure (NASDAQ:QURE) Stock Price Down 4.8% – What’s Next?

Shares of uniQure (NASDAQ:QURE) fell 4.8% on Tuesday . The stock traded as low as $15.08 and last traded at $15.05. 74,702 shares were traded during mid-day trading, a decline of 93% from the average session volume of 1,144,552 shares. The stock had previously closed at $15.80.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Stifel Nicolaus increased their price objective on uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, December 16th. Leerink Partners upped their price objective on uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a report on Wednesday, December 11th. The Goldman Sachs Group upped their price objective on shares of uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, December 12th. StockNews.com upgraded uniQure to a “sell” rating in a report on Wednesday, December 11th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 price target on shares of uniQure in a research report on Tuesday, January 21st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $40.00.

uniQure Stock Down 0.2 %

The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The company has a market capitalization of $741.19 million, a price-to-earnings ratio of -3.08 and a beta of 0.41. The firm’s 50-day moving average price is $13.31 and its 200 day moving average price is $8.84.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The business had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. On average, sell-side analysts forecast that uniQure will post -3.74 EPS for the current fiscal year.

Insider Activity

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the sale, the chief executive officer now directly owns 597,915 shares in the company, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 4.74% of the company’s stock.

Institutional Trading of uniQure

A number of institutional investors have recently modified their holdings of the company. RTW Investments LP purchased a new stake in shares of uniQure during the third quarter valued at approximately $49,000. China Universal Asset Management Co. Ltd. raised its holdings in uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 3,663 shares during the period. Atria Investments Inc purchased a new position in uniQure in the 3rd quarter worth approximately $53,000. Quarry LP purchased a new position in uniQure during the third quarter valued at $58,000. Finally, Vanguard Personalized Indexing Management LLC increased its stake in uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 2,306 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.